To accelerate and enhance regional growth, Lunit is evolving its global operations under a unified structure. Lunit ...
New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of ...
New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best ...
The 5th Binaytara Precision Oncology Summit, a two-day conference chaired by Dr. Mark Pegram, convenes in San Francisco on October 24-25, 2025. The summit is dedicated to redefining cancer treatment ...
TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. Preserves DNA integrity in challenging clinically ...
An NYC Health + Hospitals/Elmhurst (N.Y). team recently performed the system’s first stereotactic radiosurgery treatment using Varian’s TrueBeam linear accelerator. The hospital’s linear accelerator ...
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 ...
The current commentary examines the fundamental tensions between conventional evidence synthesis methods and the personalized clinical trial paradigms emerging from the remarkable scientific advances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback